Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
New Hemophilia B Drug Candidate Presented at ISTH Congress
 

Inspiration Biopharmaceuticals, Inc., a Laguna Niguel, CA-based company founded in 2004, presented preclinical data on the development of a new recombinant factor IX drug at the 21st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held July 6-12, 2007, in Geneva, Switzerland. The drug candidate, which is being developed using Inspiration’s patented recombinant protein manufacturing technologies, is for patients with hemophilia B.

An oral presentation and a poster session were given on the new drug candidate at the ISTH Congress. The oral report, "Glycosylation of the Activation Peptide of Factor IX Determines Plasma Half Life," was given by Dougald M. Monroe, PhD, Associate Professor, UNC School of Medicine, The University of North Carolina at Chapel Hill. The poster, "N-Glycan Sialylation is Important for In Vivo Recovery of Recombinant Factor IX," was presented by Michael Griffith, PhD, president and CEO of Inspiration Biopharmaceuticals, Inc.

"Inspiration Biopharmaceuticals is seeking to revolutionize the treatment of hemophilia by providing high quality, less costly factor products. Our ultimate goal is to increase accessibility to prophylactic treatment and improve the quality of life for people suffering from hemophilia," said Griffith. "We are therefore excited about the progress that we have made in advancing our protein manufacturing technology. We look forward to initiating clinical trials this year."

Source: Inspiration Biopharmaceuticals, Inc. press release dated July 11, 2007